IM

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop <u>Disclosure</u> Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: 9 13/06

By: Winsome A. St Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Martin Dugas, et al.

SERIAL NO.: 10/575,829

) ART UNIT: Unassigned

PCT FILING DATE: NOVEMBER 4, 2004

FOR: METHOD FOR DISTINGUISHING

) DOCKET NO 22328-US

IMMUNOLOGICALLY DEFINED ALL

SUBTYPE

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure. Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

SEP 18 2006

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.

Applicants wish to provide the USPTO with electronic copies of WO 03/039433A2 and WO 03/083140, where the pages are in excess of 2,900 respectively.

2

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date: <u>9/12/06</u>

Fax: (510) 814-2973

Robert W. Mann Reg. No. 48,555

Correspondence Address: Roche Molecular Systems, Inc 1145 Atlantic Avenue Alameda, CA 94501 Tele: (510) 814-2800

U.S. Department of Commerce Patent and Trademark Office					Atty. Docket No. 22328-US Serial No. 10/575,829				
LIST OF IN (Use several sh		MATION CITED BY APPL f necessary)	ICANT	Appli	cants: Martin Dugas	s, et al.			
GED 3.0 A					national Filing Date:	Group: N/A			
		图 2008	.G/	TENT 1	DOCUMENTS				
* EXAMINER INITIAL		DOCUMENT NUMBERAN	ISSUE I		NAME	CLAS	S SUBCLASS	FILING DATE IF APPROPRIATE	
	1	5,210,015	05/11/93		Gelfand, et al	435	6	08/06/90	
	2	5,445,934	08/29/95		Fodor, et al	435	6	09/30/92	
	3	5,487,972	01/30/96		Gelfand, et al	435	6	01/05/93	
	4	5,700,637	12/23/97		E. Southern	435	6	04/19/94	
	5	5,744,305	04/28/98		Fodor, et al	435	6	06/06/95	
	6	5,804,375	09/08/98		Gelfand, et al	435	6	04/25/95	
· · · · · · · · · · · · · · · · · · ·	7	5,945,334	08/31/99	-	Besemer, et al	435	287.2	06/07/95	
	8	6,174,670 B1	01/16/01		Wittwer, et al	435	6	06/04/97	
	9	2003/0138793 A1	07/24/03	-	Su, et al	435	6	06/10/02	
							•	· i.	
		¥ · · · · · · · · · · · · · · · · · · ·	·		NT DOCUMENTS				
		DOCUMENT NUMBER	PUBLICA DAT		COUNTRY	CLAS	SUBCLASS	TRANSLATION	
	10	0 373 203 B1	08/31/94		EP				
	11	0 619 321 B1	01/07/90		EP				
	12	1 043 676 A1	10/11/00		EP				
	13	1 109 020 A1	06/20/200)1	EP				
	14	1 308 522	05/07/03		EP				
	15	WO 92/02638	02/20/92		PCT .				
	16	WO 03/039443 A2	05/15/03		PCT				
	17	WO 03/083140 A2	10/09/03		PCT				
	18	WO 2005/045438	05/19/05		PCT				
	19	EP2004/012459 Search Report	06/28/05		PCT				
		OTHER ART (In	cluding A	uthor,	Title, Date, Pertine	ent Page	s, Etc.)		
	20	Alizadeh, A., et al., 1999, "T Gene Expression in Normal Biology, Volume LXIV, <i>Col</i>	he Lympho and Malig	ochip: A nant Lyr	Specialized cDNA Mic nphocytes", Cold Spri	croarray f ngs Harb	or the Genomic-sca	le Analysis of Quantitative	
	22		Brown, M., et al, 2000, "Knowledge-based analysis of microarray gene expression data by using support vector machines, <i>PNAS</i> , 97(1):262-267						
	23	Chen, J-S., et al., 2001, "Ide lymphoblastic leukemia", B	ntification			ng minim	al residual disease i	n acute	
	24	Deutsch, J., 2003, "Evolutio				sets in mi	croarray prediction	n", Bioinformatics,	

Attorney Docket: 22328-US Serial No. 10/575,829 Page 2 of 2

	25	Dugas, M., et al., 2001, "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping", <i>Leukemia</i> , 15:1805-1810						
_	26	Dugas, M., et al., 2002, "Impact of Integrating Clinical and Genetic Information", In Silico Biology, 2:383-391						
	27	Furey, T., et al., 2000, "Support vector machine classification and validation of cancer tissue samples using microarry expression data", <i>Bioinformatics</i> , 16(10):906-914						
	28	Golub, T., et al, 1999, "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, 286:531-537						
	Haferlach, T., et al., 2002, "Abstract: Gene Expression Profiling is Able to Reproduce Different Phenotypes as Defined by the FAB Classification", <i>Blood</i> , 100, Abstract 731							
	30 Harlow, E., et al, 1988, "Antibodies A Laboratory Manual", Cold Spring Harbor Laboratory							
	31	Koehler, G., et al., 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", <i>Nature</i> . 256:495-497						
	32	Expression Profiling", Blood, 100, Abstract 4287						
	33	Kohlmann, A., et al., 2003, "Molecular Characterization of Acute Leukemias by Use of Microarray Technology", Genes, Chromosomes & Cancer, 37:396-405						
	34	Liu, G., et al., 2003, "NetAffx: Affymetrix probesets and annotations", Nucleic Acids Research, 31(1):82-86						
	35	Sambrook, J., et al., 1989, "Molecular Cloning A Laboratory Manual Second Edition", Cold Spring harbor Laboratory Press,						
	36	Storey, J., et al., 2003, "Statistical significance for genomewide studies," PNAS, 100(16):9440-9445						
	37	Tsutsumi, S., et al., 2001, "Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements," <i>Cancer Research</i> , 63:4882-4887 Yeoh, e., et al., 2002, "Classification, subtype discovery, and predication of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling", <i>Cancer Cell</i> , 1:133-143						
	38							
EXAMINER		DATE CONSIDERED						
		if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in onsidered. Include copy of this form with next communication to applicant.						